Published online Sep 16, 2021. doi: 10.12998/wjcc.v9.i26.7643
Peer-review started: June 8, 2021
First decision: June 30, 2021
Revised: July 9, 2021
Accepted: July 28, 2021
Article in press: July 28, 2021
Published online: September 16, 2021
Although targeted therapies and immunotherapies have been effective against several malignancies, the respective monotherapies are limited by low and/or short-term responses. Specific inhibitors of oncogenic signaling pathways and tumor-associated angiogenesis can activate the anti-tumor immune responses by increasing tumor antigen presentation or intratumor T cell infiltration. Additional insights into the effects and mechanisms of targeted therapies on the induction of anti-tumor immunity will facilitate development of rational and effective combi
Core Tip: There has been considerable interest in combining systemic and immune-related therapies for the anti-tumor treatment of cancer. Additional insights into the effects and mechanisms of targeted therapies on the induction of anti-tumor immunity will aid the development and design of effective strategies, with the synergistic po